An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Enthesitis-related Arthritis
Juvenile Psoriatic Arthritis

Interventions

DRUG: Bimekizumab

Sponsor

UCB Biopharma SRL